Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study

被引：19

作者：

Takeuchi, Tsutomu ^{[1
]}

Miyasaka, Nobuyuki ^{[2
]}

Tatsuki, Yoshihiko ^{[3
]}

Yano, Toshiro ^{[3
]}

Yoshinari, Toru ^{[3
]}

Abe, Tohru ^{[4
]}

Koike, Takao ^{[5
]}

机构：

[1] Keio Univ, Div Rheumatol, Dept Internal Med, Sch Med,Shinjuku Ku, Tokyo 1608582, Japan

[2] Tokyo Med & Dent Univ, Dept Med & Rheumatol, Grad Sch, Bunkyo Ku, Tokyo, Japan

[3] Mitsubishi Tanabe Pharma Corp, Osaka, Japan

[4] Saitama Med Univ, Saitama Med Ctr, Kawagoe, Saitama, Japan

[5] Sapporo Med Ctr NTT EC, Chuo Ku, Sapporo, Hokkaido, Japan

来源：

关键词：

TNF-ALPHA THERAPY; DISEASE-ACTIVITY; DOSE-ESCALATION;

D O I：

10.1136/annrheumdis-2011-201069

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1583 / 1585

页数：3